Skip to content
Screener

Amphastar Pharmaceuticals AMPH Debt-to-equity

Discontinued — last reported Q4 '21

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
15.2×+10.6×
Emergent Biosolutions logo
Emergent BiosolutionsEBS
1.7×+0.5×
Viatris logo
ViatrisVTRS
1×0.0×
Opko Health logo
Opko HealthOPK
0×0.0×
AptarGroup logo
AptarGroupATR
0.5×+0.1×

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M—
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$873.48M-28.0%
Enterprise value$1.34B-20.6%
P/E11.1×+2.1×
P/S1.2×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%—
Current ratio2.4×-0.9×

Where this comes from

Calculated from Amphastar Pharmaceuticals’s reported figures.

total debt/total stockholders equity=0.2×

Based on the most recent quarter.

The source filing: Amphastar Pharmaceuticals’s 10-K, filed March 1, 2023. Open the filing →

Filed
Mar 1, 2023
Fiscal year
FY2022
Accession
0001297184-23-000019

FAQ

What is Amphastar Pharmaceuticals's debt-to-equity?
Amphastar Pharmaceuticals (AMPH) reported debt-to-equity of 0.2× in Q4 2021.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Amphastar Pharmaceuticals's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude